Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Padmaja V. Venuturumilli

Oncology | Pediatrics
Michigan Healthcare Professionals
Michigan Healthcare Professionals PC
1221 Pine Grove Ave, 
Port Huron, MI 
Accepting New Patients
Offers Telehealth

Experienced in WT1-Related Wilms Tumor Syndromes
Michigan Healthcare Professionals
Michigan Healthcare Professionals PC
1221 Pine Grove Ave, 
Port Huron, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Padmaja Venuturumilli is an Oncologist and a Pediatrics provider in Port Huron, Michigan. Dr. Venuturumilli is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Chronic Familial Neutropenia, Paget Disease of the Breast, Hemangioma Thrombocytopenia Syndrome, Bone Marrow Aspiration, and Vertebroplasty. Dr. Venuturumilli is currently accepting new patients.

Her clinical research consists of co-authoring 2 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Pediatrics
Licenses
Pediatrics in MI
Hospital Affiliations
Beaumont Hospital - Dearborn
Beaumont Hospital, Troy
Beaumont Hospital - Grosse Pointe
Trinity Health Oakland Hospital
Beaumont Hospital Royal Oak
Languages Spoken
English
Hindi
Kannada
Tamil
Telugu
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

MICHIGAN HEALTHCARE PROFESSIONALS PC
1221 Pine Grove Ave, Port Huron, MI 48060
Call: 810-987-5000
Other Locations
MICHIGAN HEALTHCARE PROFESSIONALS PC
27900 Grand River Ave, Farmington Hills, MI 48336

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


5 Clinical Trials

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Gemcitabine, Cisplatin, Methotrexate, Vinblastine, Doxorubicin, Filgrastim
Study Phase: Phase 2
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drugs: tucatinib, capecitabine, trastuzumab
Study Phase: Phase 2
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus Cyclophosphamide, Doxorubicin and Vincristine (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS)
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus Cyclophosphamide, Doxorubicin and Vincristine (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS)
Enrollment Status: Completed
Publish Date: October 28, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

2 Total Publications

Rapid clinical and radiographic improvement after intrathecal trastuzumab and methotrexate in a patient with HER-2 positive leptomeningeal metastases.
Rapid clinical and radiographic improvement after intrathecal trastuzumab and methotrexate in a patient with HER-2 positive leptomeningeal metastases.
Journal: Acta oncologica (Stockholm, Sweden)
Published: June 05, 2012
View All 2 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Sheela Tejwani
Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Sheela Tejwani
Oncology | Hematology

Henry Ford Health System

2799 W Grand Blvd, 
Detroit, MI 
 (54.3 miles away)
313-916-2600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sheela Tejwani is an Oncologist and a Hematologist in Detroit, Michigan. Dr. Tejwani is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Adult Soft Tissue Sarcoma, WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, Rhabdomyosarcoma, and Bone Marrow Aspiration. Dr. Tejwani is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Richard Zekman
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Richard Zekman
Oncology

Michigan Healthcare Professionals PC

3577 W 13 Mile Rd, 
Royal Oak, MI 
 (50.5 miles away)
Languages Spoken:
English
See accepted insurances

Richard Zekman is an Oncologist in Royal Oak, Michigan. Dr. Zekman is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Paget Disease of the Breast, Bone Marrow Aspiration, and Endoscopy.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Andrew A. Muskovitz
Hematology Oncology | Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Andrew A. Muskovitz
Hematology Oncology | Hematology | Oncology

Michigan Healthcare Professionals PC

1221 Pine Grove Ave, 
Port Huron, MI 
 (0.1 miles away)
810-987-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Muskovitz is a Hematologist Oncology specialist and a Hematologist in Port Huron, Michigan. Dr. Muskovitz is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Thrombocytopenia, Bone Marrow Aspiration, and Ureteroscopy. Dr. Muskovitz is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Venuturumilli's expertise for a condition
ConditionClose
    • Distinguished
    • Anal Cancer
      Dr. Venuturumilli is
      Distinguished
      . Learn about Anal Cancer.
      See more Anal Cancer experts
    • Chronic Familial Neutropenia
      Dr. Venuturumilli is
      Distinguished
      . Learn about Chronic Familial Neutropenia.
      See more Chronic Familial Neutropenia experts
    • Colorectal Cancer
      Dr. Venuturumilli is
      Distinguished
      . Learn about Colorectal Cancer.
      See more Colorectal Cancer experts
    • Familial Colorectal Cancer
      Dr. Venuturumilli is
      Distinguished
      . Learn about Familial Colorectal Cancer.
      See more Familial Colorectal Cancer experts
    • Hemangioma Thrombocytopenia Syndrome
      Dr. Venuturumilli is
      Distinguished
      . Learn about Hemangioma Thrombocytopenia Syndrome.
      See more Hemangioma Thrombocytopenia Syndrome experts
    • Lynch Syndrome
      Dr. Venuturumilli is
      Distinguished
      . Learn about Lynch Syndrome.
      See more Lynch Syndrome experts
    View All 8 Distinguished Conditions
    • Advanced
    • Agranulocytosis
      Dr. Venuturumilli is
      Advanced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • Ampullary Cancer
      Dr. Venuturumilli is
      Advanced
      . Learn about Ampullary Cancer.
      See more Ampullary Cancer experts
    • Anemia
      Dr. Venuturumilli is
      Advanced
      . Learn about Anemia.
      See more Anemia experts
    • Angiosarcoma
      Dr. Venuturumilli is
      Advanced
      . Learn about Angiosarcoma.
      See more Angiosarcoma experts
    • Breast Cancer
      Dr. Venuturumilli is
      Advanced
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Cholangiocarcinoma (Bile Duct Cancer)
      Dr. Venuturumilli is
      Advanced
      . Learn about Cholangiocarcinoma (Bile Duct Cancer).
      See more Cholangiocarcinoma (Bile Duct Cancer) experts
    View All 21 Advanced Conditions
    • Experienced
    • Adrenal Cancer
      Dr. Venuturumilli is
      Experienced
      . Learn about Adrenal Cancer.
      See more Adrenal Cancer experts
    • Adrenocortical Carcinoma
      Dr. Venuturumilli is
      Experienced
      . Learn about Adrenocortical Carcinoma.
      See more Adrenocortical Carcinoma experts
    • Adult Soft Tissue Sarcoma
      Dr. Venuturumilli is
      Experienced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Venuturumilli is
      Experienced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Alveolar Soft Part Sarcoma
      Dr. Venuturumilli is
      Experienced
      . Learn about Alveolar Soft Part Sarcoma.
      See more Alveolar Soft Part Sarcoma experts
    • Anaplastic Thyroid Cancer
      Dr. Venuturumilli is
      Experienced
      . Learn about Anaplastic Thyroid Cancer.
      See more Anaplastic Thyroid Cancer experts
    View All 91 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2025 All Rights Reserved